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Intrapleural fibrinolysis has been investigated for the treatment of pleural effusion for several decades.
Fibrinolytics have the ability to break up fibrin and loculations that characterize complicated pleural
effusions, facilitating drainage. Older fibrinolytics such as urokinase and streptokinase have been
replaced by tissue plasminogen activator (tPA) for this indication due to product availability and a
more favorable safety profile. The literature supports tPA as a treatment approach for this indication in
adult patients, and the use of tPA has become a standard management approach in this population.
Over the past decade, data on the efficacy of intrapleural fibrinolytic therapy in children have also
been generated, which now support the use of fibrinolysis as a treatment alternative to more invasive
therapeutic options such as surgical intervention. In this review, we discuss the pathophysiology, diag-
nosis, and treatment of parapneumonic effusion and empyema, with a focus on intrapleural fibrinoly-
sis, specifically tissue plasminogen activator, in the pediatric population. Recent articles provide
sufficient evidence to support the use of this drug in pediatric patients for the management of pleural
effusions; however, due to study heterogeneity, questions remain that may be addressed in future
studies.
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Pleural effusion is defined as the accumulation
of excess fluid in the pleural space between the
lung and the chest wall.1 Several possible etiolo-
gies for pleural effusion are heart failure,
trauma, liver disease, and malignancy, as well as
chylous and transudative effusions.2 However, in
the pediatric population, pleural effusions are
most commonly caused by infection—typically a
bacterial pneumonia—and are thus termed para-
pneumonic effusions.3 Empyemas are more
advanced, organized effusions and refer to locu-
lations or pus in the pleural space.1 Although
not all effusions require intervention, those that
are infectious in origin, are more advanced, or
large enough in volume to affect respiratory
dynamics may necessitate medical and/or surgi-
cal treatment.4–6
After the introduction of routine immuniza-
tion of infants with the 7-valent pneumococcal
conjugate vaccine in 2000, the hospitalization
rate associated with all-cause pneumonia in chil-
dren younger than 2 years of age declined by
33% in the United States.7 Despite this decrease,
the rate of empyema complicating community-
acquired pneumonia in children has risen across
that same time period; specifically, the reported
rate was 3.5 cases/100,000 children from 1996–
1998, whereas the rate was 7 cases/100,000 chil-
dren from 2005–2007.7 Pleural effusion may
complicate up to 60% of pneumonias.8–10 Symp-
toms are related to the size and extent of the
pleural effusion and may include fever, tachyp-
nea, and increased oxygen requirements.9
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Effusions may subsequently progress to empy-
emas, which increase the risk of morbidity and
mortality. Mortality associated with empyema is
roughly 20% in adults but is significantly lower
in children.4, 9 However, empyema in the pediat-
ric population is still associated with significant
morbidity including restrictive lung disease and
the necessity for advanced medical and invasive
surgical interventions.4
Intrapleural fibrinolysis was initially investi-
gated nearly 60 years ago for the treatment of
empyema and has now become a standard man-
agement approach in adult patients.10, 11 Over
the past decade, data on the efficacy of fibrino-
lytic therapy in children have been generated,
which now support fibrinolysis as a treatment
alternative to invasive surgical interventions. In
this review, we discuss the pathophysiology,
diagnosis, and treatment of parapneumonic effu-
sion and empyema, with a focus on intrapleural
fibrinolysis with tissue plasminogen activator
(tPA), in the pediatric population.
Pathophysiology
Parapneumonic effusions and empyemas are
commonly caused by the typical pathogens
responsible for bacterial pneumonia: Streptococcus
pneumoniae, Streptococcus pyogenes, Staphylococ-
cus aureus, Haemophilus influenzae, Pseudomonas
aeruginosa, and Mycoplasma pneumoniae.3, 4, 12, 13
In response to infection, pleural secretions and
capillary permeability are increased, resulting in
an accumulation of fluid. This fluid collection—
the pleural effusion—can cause a mass effect,
resulting in restriction of lung expansion and
eventual increased oxygen requirements.11, 12
The stimulation of the inflammatory cascade may
also lead to subsequent activation of the coagula-
tion cascade and fibrin deposition, ultimately
leading to the formation of an empyema.11, 12 The
disease process develops along a time continuum
through three stages: exudative, fibrinopurulent,
and organizational. The risk of poor outcome
increases as the disease progresses. The presence
of pus is typically associated with the worst out-
comes; however, any of the criteria associated
with moderate- or high-risk effusions confer a
risk of poor outcome.5
The exudative stage is characterized by a rapid
accumulation of free-flowing fluid in the pleural
space. This is secondary to interstitial fluid
crossing the pleura and entering the pleural
space due to inflammation and increased capil-
lary permeability.1, 12 At this point, the effusion
is still considered to be uncomplicated. However,
the fluid frequently becomes secondarily infected
and marks the transition of the effusion into the
fibrinopurulent stage. The fluid collection at this
stage becomes increasingly complicated as the
infection leads to continued inflammation.12
Increased metabolic activity due to microbial
growth affects the chemistry of the pleural fluid
and causes the glucose concentration and pH to
drop.7 Neutrophil lysis also causes a concurrent
rise in the lactate dehydrogenase concentration.7
In this phase, the coagulation cascade and fibri-
nolysis become imbalanced, leading to fibrin
deposition, loculations, and adhesions.12 In the
third phase of disease progression, the organiza-
tional phase, the fluid collection develops into
an empyema. As advanced complicated effusions
become organized, pus develops within the pleu-
ral space, and fibroblasts produce a thick,
fibrous pleural peel.12 Loculations develop fur-
ther, and the thickened collection creates a mass
effect, preventing effective lung expansion.12
Table 1 depicts the physiologic characteristics of
each of these three stages.
Diagnosis
Multiple diagnostic modalities are available
for evaluating pleural effusion in pediatric
patients. The main imaging options include
chest radiograph (CXR), ultrasound, and com-
puted tomography (CT).9 Initial CXR is often
used to identify a possible effusion; however, it
cannot specifically differentiate between free-
flowing effusion and loculated empyema, or
even pneumonia-related lung consolidation.9, 14
Serial CXRs may be particularly helpful when
evaluating disease progression and the effect of
therapy in children who are not clinically
improving with standard care.3, 13 In addition,
CXR can help identify other conditions associ-
ated with parapneumonic effusion and empyema
such as pneumothorax, lobar consolidation, air
fluid levels, and pneumatoceoles.14
The American Pediatric Surgical Association
(APSA) Outcomes and Clinical Trials Committee
published recommendations in 2012 for the
diagnosis and management of empyema in chil-
dren. The APSA recommends ultrasound as the
first-line option for imaging in children with
suspected pleural effusion based on CXR.9 Ultra-
sound has many advantages in this population
including low relative cost, portability, and lack
of associated radiation. However, the utility of
ultrasound is dependent on the quality of images
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and operator expertise. Further, ultrasound may
not be readily available at all institutions. Com-
puted tomography offers an alternative diagnos-
tic modality. Similar to ultrasound, CT provides
information about pleural thickening and locula-
tions; however, it may be less accurate than
ultrasound in identifying fibrin deposits. Com-
puted tomography is significantly more expen-
sive than ultrasound. Additionally, radiation
exposure associated with routine CT use may
increase the long-term risk of malignancy. The
APSA recommends using CT only in complex
cases in which ultrasound is inadequate or addi-
tional information is required for surgical deci-
sion making.
Definitive diagnosis is possible with diagnostic
thoracentesis, a procedure involving the aspira-
tion of pleural fluid from the effusion with a
needle.10 The collected fluid is analyzed for
characteristic diagnostic findings across the
stages of disease (Table 1).
Treatment
A summary of the classic treatment
approaches across the stages of disease is
included in Table 1. Exudative (or simple)
parapneumonic effusions are often effectively
managed with medical therapy alone. Early initi-
ation of appropriate antibiotics can decrease the
severity and duration of effusions.3 Empiric ther-
apy should be selected based on the suspicion
for community- versus hospital-acquired infec-
tions, the patient’s immunization status, as well
as local resistance patterns and suspicion for
more virulent organisms such as community
acquired methicillin-resistant Staphylococcus
aureus.3, 4, 10, 13 The pleural fluid may also be
cultured, obtained either by thoracentesis or
drainage with tube thoracostomy, in order to
help further guide and tailor antibiotic therapy.3
In patients with more advanced (or complex)
pleural effusions, antibiotic therapy alone may
be insufficient, and additional drainage of the
pleural fluid is necessitated.3 Initial options for
drainage of pleural fluid include therapeutic tho-
racentesis or chest tube placement as monother-
apy, or chest tube placement with concomitant
chemical debridement (e.g., fibrinolytic ther-
apy).3, 4 First-line therapy often includes chest
tube drainage; but, therapeutic thoracentesis is
somewhat less invasive and may be pursued ini-
tially.12 If thoracentesis is used as first-line ther-
apy, the 2011 British Thoracic Society
publication recommends placement of a chest
tube after the first failed thoracentesis attempt
(e.g., fluid reaccumulation).3 However, drainage
by repeated thoracentesis has not been com-
pared with chest tube placement alone.
Drainage may be unachievable at more
advanced, or complex, stages of pleural effusion
due to fibrin deposition and loculations.8 In
Table 1. Phases of Pleural Effusion1, 8, 12
Characteristic
Exudative Phase Fibrinopurulent Phase Organization Phase
Uncomplicated Complicated
Risk of Poor Outcome Low Moderate High
Fluid
characteristics
Thin, free-flowing,
no pus or fibrin
Low white blood
cell count
Protein present
Low lactic acid
dehydrogenase
level (< 3 9 ULN)
Normal pH (≥ 7.2)
Glucose level
> 60 mg/dl
Thicker, cloudy fluid
Fibrin present
Increased white blood
cell count
High lactic acid
dehydrogenase
level (> 3 9 ULN)
Low pH (< 7.2)
Glucose level < 60 mg/dl
Very thick
Pus and fibrin peel present
Loculations present
Increased white blood
cell count
High lactic acid
dehydrogenase
level (> 3 9 ULN)
Low pH (< 7.2)
Glucose level < 60 mg/dl
Gram stain
and culture
Unknown or Negative Positive Positive with presence
of pus
Classic treatment
approach
Antibiotics Antibiotics
Drainage of pleural fluid by
therapeutic thoracentesis or
chest tube placement
Antibiotics
Drainage of pleural fluid
by therapeutic thoracentesis
or chest tube placement
Invasive surgical procedures
(video-assisted thoracoscopic
surgery, open thoracotomy)
Role for fibrinolytics No Yes Yes
ULN = upper limit of normal.
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patients unable to achieve sufficient drainage of
pleural fluid, additional intervention is war-
ranted in order to avoid continued lung restric-
tion, increased oxygen requirements, and
progression to higher levels of respiratory sup-
port such as mechanical ventilation or extracor-
poreal membrane oxygenation.3 The historical
gold standard of care for more progressive
empyema is surgical intervention. The two most
common surgical procedures for progressive
empyema include minimally invasive video-
assisted thoracoscopic surgery (VATS) and open
thoracotomy for decortication of loculations.5
The VATS procedure is currently considered
the first-line surgical option for qualifying
patients. It is a newer, highly effective technique
that allows for debridement and decortication of
loculations through minimally invasive access
and direct visual inspection of the pleural space
with the use of a laprascope.3 As a minimally
invasive surgery, patients may experience less
postoperative pain and a quicker recovery per-
iod compared with other surgical options. Fur-
thermore, the risk of long-term associated
morbidity is lessened. However, some patients
are not candidates for this procedure and/or
may eventually require a more invasive
approach. Open thoracotomy with decortication,
although extremely effective and thorough,
remains the most invasive option for debride-
ment and may be required in up to 35% of
patients who fail conservative medical measures
or in those who fail the VATS procedure.8 Com-
pared with VATS, the open thoracotomy proce-
dure requires a larger surgical incision, is highly
invasive, and is associated with significantly
more postoperative pain, a longer recovery per-
iod, and additional postoperative morbidity
(e.g., potential for rib fusion and scoliosis). Both
VATS and open thoracotomy are associated with
the risk of postsurgical complications such as
bleeding and the requirement for extended ven-
tilator support.
Fibrinolytic Pharmacology and
Pharmacokinetics
Since the early 1950s, fibrinolytic therapy has
emerged as a less invasive alternative treatment
approach to the more invasive surgical proce-
dures for complicated effusions described above.
The theory behind the use of fibrinolytics is
rooted in the idea that complicated parapneu-
monic effusions and empyemas are characterized
by fibrin deposition.8 The ability to break up
fibrin and loculations with intrapleural fibrino-
lytics allows for greater success in achieving
drainage without further surgical or mechanical
interventions.
Although not currently available in the United
States, the first-generation fibrinolytics, strepto-
kinase and urokinase, were initially used to treat
parapneumonic effusions and empyema.15–18
Streptokinase indirectly activates the fibrinolytic
system by binding plasminogen and causing con-
formational change.12, 19 An active site is subse-
quently exposed and cleaves other plasminogen
molecules to promote the formation of plas-
min.19 Urokinase, a thrombolytic agent obtained
from human neonatal kidney cells grown in cul-
ture, works slightly differently; one plasmin mol-
ecule can be directly activated by each urokinase
molecule.12, 20 Plasmin then promotes the break-
down of fibrin.19 Although more common with
streptokinase, both agents have been associated
with adverse effects, specifically, immunologic
and hypersensitivity reactions.12 Furthermore,
an antibody-mediated response that caused inef-
fectiveness with repeat dosing was also associ-
ated with streptokinase use because its
production is bacteria based.12, 17
Tissue plasminogen activator was developed
as an answer to some of the drawbacks associ-
ated with the first-generation agents. It binds
directly to fibrin and catalyzes the conversion of
plasminogen to plasmin, leading to fibrinoly-
sis.12 Furthermore, tPA is not associated with
hypersensitivity reactions and retains its effec-
tiveness over multiple doses.12 Although the
pharmacokinetic parameters of intrapleural tPA
have not been definitively determined, when
given intravenously, the volume of distribution
approximates plasma volume. Clearance is rapid
from the plasma through metabolism in the
liver, and the half-life of tPA is less than 5 min-
utes in adult patients.21
Approved indications for systemic tPA include
management of acute myocardial infarction, acute
ischemic stroke within 3 hours of stroke symp-
tom onset, and acute massive or unstable pulmo-
nary embolism in adults.21 Tissue plasminogen
activator is also approved for restoring patency to
central venous access devices.22 Unapproved indi-
cations include treatment of arterial thrombosis
and fistula thrombosis, ocular surgery, vascular
graft occlusion, venous thromboembolism, and
intrapleural use.23
Absolute contraindications to systemic tPA
therapy include previous allergic reaction,
trauma within the previous 48 hours, or bron-
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chopleural fistula.12, 19 Relative contraindica-
tions include history of hemorrhagic stroke;
coagulation deficiencies; and major thoracic,
abdominal, or cranial surgery within the previ-
ous 2 weeks.12, 19 Contraindications to intraple-
ural administration of tPA are not well
established and are founded on clinical experi-
ence and safety risks published in the literature.
Supporting Literature in Adults
The use of fibrinolytic therapy is well estab-
lished in the literature in adults, with numerous
case reports, retrospective reviews, and random-
ized trials supporting its use for the treatment
of complicated pleural effusions and empy-
emas.24–30 A comprehensive review of the adult
literature was provided in a 2010 publication.12
Intrapleural tPA has demonstrated improved
chest tube drainage, resolution of symptoms,
decreased need for invasive surgical procedures,
and shorter hospital stays.12 The literature
supporting the use of intrapleural tPA in adults,
however, is heterogeneous with regard to indica-
tions, therapeutic end points, dosing, frequency,
duration of treatment, and dwell time.
A recent investigation in the adult population
evaluated dual intrapleural therapy with tPA
plus recombinant human dornase alfa.29 Empy-
ema fluid typically contains large amounts of
extracellular DNA. Dornase alfa (or DNase)
degrades polymerized deoxyribonucleoproteins
in bacterial and mammalian cells, theoretically
reducing pus viscosity and facilitating drain-
age.12, 29 In a multicenter, prospective trial, 210
adults with parapneumonic effusions were ran-
domized to receive one of four possible treat-
ments: tPA plus dornase alfa, dornase alfa plus
placebo, tPA plus placebo, or double placebo.29
Dornase alfa 5 mg plus tPA 10 mg were given
twice/day for 3 days, with a dwell time of
1 hour. The group receiving combination ther-
apy with dornase alfa and tPA showed a signifi-
cant decrease in the area of pleural opacity on
CXR. Patients who received dual therapy were
also less likely to require surgical referral, had
increased pleural fluid drainage, and had
decreased total length of hospital stay. The
other three treatment arms did not show a sta-
tistically significant benefit. No significant differ-
ences in adverse effects among the groups were
reported. Thus, dual therapy with intrapleural
tPA and dornase alfa is concluded to be safe
and effective in adults with parapneumonic
effusion.
Supporting Literature in Pediatric Patients
Since the 1990s, investigations of fibrinolytic
therapy have expanded into the pediatric popu-
lation. The efficacy of intrapleural fibrinolytics
in the pediatric population has been demon-
strated in several retrospective studies, case
studies, and case series (Table 2), as well as one
prospective study.
Retrospective Data
Early Use of tPA in Pediatric Patients
Early case reports and case series described
successful treatment with tPA in pediatric
patients as demonstrated by resolution of clinical
signs and symptoms, increased chest tube drain-
age, improvements seen on CXR and CT scan,
and prevention of surgical intervention.8, 31 The
first published case of successful intrapleural
tPA in a pediatric patient, published in 2001,
suggested preliminary efficacy in the pediatric
population.8 A 6-year-old boy received tPA 5 mg
diluted in 50 ml of normal saline by chest tube
instillation for management of pleural effusion.
The chest tube was clamped for 1 hour, and a
second dose was given 8 hours later. Chest tube
drainage was increased, the CXR demonstrated
improvement, and invasive, surgical interven-
tions were avoided.
Similar findings were published in 2003.31 A
10.3-kg, 16-month-old female received tPA 2 mg
directly instilled intrapleurally for a persistent
parapneumonic effusion, decreased chest tube
drainage, and ongoing clinical signs and symp-
toms despite appropriate antibiotic therapy.
Over 6 days, the patient received four doses of
tPA, each dwelling for a 4-hour period. Treat-
ment success was measured by increased chest
tube drainage, improvement of clinical signs and
symptoms, and resolution seen on both CT scan
and CXR.
A small case series of six children aged
2–13 years old evaluated the efficacy of tPA as
measured by the difference in chest tube output
before and after tPA administration.32 Patients
received tPA 2–5 mg mixed in normal saline
with a dwell time ranging from 4–6 hours. Doses
were repeated every 12–24 hours until resolution
was observed on CXR or therapy was no longer
deemed to be efficacious (e.g., volume instilled
equaled volume drained). Patients received, on
average, a total of 3–6 doses. In addition, unlike
any other published report, patients were rotated
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at 30-minute intervals into the Trendelenburg,
reverse Trendelenburg, and left and right lateral
decubitus positions. The primary end point of
the difference in pleural fluid drainage before
tPA (mean  SD 22.5  18.4 ml) versus after
tPA (141.7  28.3 ml) administration was signif-
icant (p<0.0001). Further, five of the six patients
achieved effusion resolution.
A larger retrospective case series of 58 chil-
dren with complicated parapneumonic effusion,
confirmed results of earlier case reports.33 Chil-
dren aged 7 months–17 years were treated with
weight-based dosing of tPA: 0.1 mg/kg/dose
mixed in 10–30 ml of normal saline (maximum
dose of 3 mg). The dwell time ranged from 45–
60 minutes, repeated every 8 hours for 3–
4 days, until chest tube drainage was less than
25 ml/12-hour period. The mean number of
doses/patient was 10. Of the 58 patients evalu-
ated, 54 achieved resolution, and there were no
30-day recurrences and no deaths reported. Of
the four patients who failed tPA therapy, three
underwent the VATS procedure, and one patient
had open thoracotomy with decortication and
debridement. In a second large case series, 71
children, aged 6 months–18.8 years, with empy-
ema or parapneumonic effusion and decreased
chest tube output and pleural thickening seen
on CXR were evaluated.34 This retrospective
case series was completed between 1995 and
2002. As urokinase was still on the U.S. market
from 1995–1998, patients received either uroki-
nase 25,000–100,000 IU (26 patients) or tPA
0.1 mg/kg diluted in 25–100 ml of normal saline
(45 patients), depending on patient age and size.
Doses were administered once/day and repeated
each day until chest tube output was less
than 40 ml/day, with a maximum of six doses.
Efficacy was demonstrated in both groups, with
70 of 71 patients achieving resolution of effusion
without the need for invasive surgical interven-
tion (99% success rate). Similarly, a decrease in
pleural thickness was observed in 70 of 71
patients and a decrease in lung opacifications
was observed in 65 of 71 patients (92% success
rate). When compared with urokinase, tPA
showed superior effects for decrease in pleural
thickness (p=0.004), lung opacification
(p=0.04), and chest tube output (p=0.001).
Timing of tPA Initiation
A large, retrospective cohort study evaluated
53 children with complicated pleural effusion:
30 children were treated with tPA, and 23 chil-
dren were managed by tube thoracostomy alone
(control group).35 The study further evaluated
the impact of the timing of tPA initiation by
subdividing the treatment group into two
groups: early tPA treatment (< 24 hrs after diag-
nosis [12 patients]) and late tPA treatment
(> 24 hrs after diagnosis [18 patients]). Patients
ranged in age from 3 months–17 years old. In-
trapleural tPA was dosed at 4 mg diluted in 30–
50 ml of normal saline and allowed to dwell for
1 hour; the median number of doses/patient was
one (range of 1–3 doses/patient). The total med-
ian pleural fluid drainage was 691 ml (range
285–7944 ml) in the late tPA group versus
360 ml (range 0–2041) in the control group
(p<0.05); however, a significant difference was
not demonstrated between the early versus late
groups. The difference in the rate of pleural
fluid drainage between the early tPA group
(7 ml/hr [range 2–29 ml/hr]) versus the control
group (3 ml/hr [range 0–27 ml/hr], p<0.01) was
significant, and the difference in the duration of
chest tube placement between the early tPA
group (84 hrs [range 45–187 hrs]) versus the
late group (209 hrs [range 87–528 hrs], p<0.01)
was significant. No surgical interventions were
required for those patients treated with tPA.
Comparison of Treatment Options
The efficacy of tPA for parapneumonic effu-
sion and the timing of tPA initiation were
described above; however, questions remain
regarding the comparative effects of tPA versus
other treatment options. A retrospective study
evaluated 54 children with pleural effusion to
make this comparison.36 In this study, patients
were divided into four groups: chest tube alone
(18 patients); chest tube with fibrinolytics (24
patients); chest tube, fibrinolytics, and surgery
(5 patients); and surgery alone (6 patients).
Children treated with intrapleural tPA were
given 2 mg diluted in 20 ml of saline every
12 hours for 48–72 hours, with a dwell time of
1 hour. Outcome variables included hospital
length of stay, duration of intensive care unit
stay, duration of leukocytosis, days from ulti-
mate therapy (i.e., the number of days from the
last required therapy [e.g., chest tube monother-
apy, chest tube plus fibrinolytic, or surgery]
until discharge), and average hospital charges.
Patients who received surgery had a longer
hospital length of stay (p=0.002), longer inten-
sive care unit stay (p=0.01), and more days from
therapy to discharge (p=0.044). In addition,
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hospital charges were lower in those patients
who did not receive surgery.
Prospective Data
To our knowledge, only one prospective, ran-
domized trial has evaluated intrapleural tPA in
pediatric patients.37 In this trial, fibrinolysis with
tPA was compared with VATS as initial treatment
in pediatric patients (< 18 yrs of age) with empy-
ema. Thirty-six patients with empyema diag-
nosed by CT or ultrasound or who had purulent
drainage with a white blood cell count
above 10 9 103/ll were randomly assigned to
undergo VATS (n=18) or to receive intrapleural
tPA therapy (18 patients). All patients were trea-
ted with similar and appropriate antibiotic regi-
mens. Patients were excluded if they had
contraindications to thoracoscopy or fibrinolysis,
any additional foci of infection, immunocompro-
mised state, or comorbid conditions requiring
hospitalization beyond empyema treatment. Chil-
dren who received tPA had 12-French chest
tubes in place. At the time of chest tube place-
ment, tPA 4 mg mixed in 40 ml of normal saline
was instilled directly into the tube, with a dwell
time of 1 hour. Treatment was repeated every
24 hours for a total of three doses. The primary
outcome measures were hospital length of stay,
posttherapy days of oxygen therapy, days until
afebrile, number of analgesic doses, requirements
for a second procedure, and total hospital cost.
Baseline demographic data were well matched
in each group. Organisms cultured from both
groups were consistent with the typical patho-
gens associated with pleural effusion. Outcome
measures were similar in the VATS versus fibri-
nolysis groups for hospital length of stay after
intervention (mean  SD 6.9  3.7 vs
6.8  2.9 days, p=0.96), posttherapy days of
oxygen (2.3  1.7 vs 2.3  2.1 days, p=0.9),
days until afebrile after intervention (3.1  2.7
vs 3.8  2.9 days, p=0.46), and number of anal-
gesic doses (22.3  28.5 vs 21.4  12, p=0.9).
Two patients in the VATS group required ongo-
ing mechanical ventilation, and 3 (16.6%) of the
18 patients treated with fibrinolysis required
VATS therapy for definitive treatment. Although
the clinical end points were not significantly dif-
ferent between groups in this study, a significant
difference in overall hospital charges was
observed between the two groups:
$11,700  2900 versus $7600  5400 in the
VATS versus fibrinolysis groups (p=0.02). Thus,
it may be concluded that initial treatment with
intrapleural tPA is a reasonable alternative to an
initial VATS procedure and is associated with a
lower total hospital cost.
Safety
Intrapleural tPA is generally well tolerated
and associated with only minor adverse
effects.31–35 Early case reports and case series
noted mild discomfort, which was relieved by
analgesics.31 One patient was reported to experi-
ence a drop in serum albumin level, with edema
and ascites; however, this was most likely sec-
ondary to significant chest tube drainage.32
Sanguineous drainage without an associated
drop in hematocrit, although reported,32 was
believed to be secondary to initial chest tube
placement rather than tPA treatment itself. An
average drop in hemoglobin of 2.5 g/dl was also
observed in one case series,33 and minor bleed-
ing into the pleural fluid has been described.34
Conversely, several reports noted no increased
risk for bleeding.8, 31, 35, 36 Frank bleeding was
described in a recent case report of a previously
healthy 6-year-old boy treated with tPA 3 mg in
30 ml of normal saline (0.1 mg/kg) for pleural
effusion.38 The patient developed clinical signs
and symptoms of blood loss (tachypnea, weak-
ness, and pallor); however, his neurologic status
remained intact, and no other signs of bleeding
were apparent. The patient’s hemoglobin level
dropped from 12.1 g/dl to 7.6 g/dl, and an infu-
sion of packed red blood cells was required. In
light of this case report as well as conflicting
safety outcomes reported in the literature,
patients should be closely monitored for changes
in hematocrit and hemoglobin and for clinical
signs and symptoms of bleeding during therapy.
Few absolute contraindications for use of tPA
exist. Potential contraindications include risk for
bleeding, such as trauma, surgery, or recent
major hemorrhage, or an allergy or hypersensi-
tivity to tPA.12, 14 Coagulopathy may also be
considered to be a relative contraindication to
tPA; however, therapy may be considered if the
coagulopathy is mild and correctable.5, 33
Remaining Questions and Future Directions
Data for tPA in pediatrics are primarily retro-
spective, with only one randomized, prospective
trial currently published.37 Nevertheless, evi-
dence supports the use of tPA as a first-line
option in pediatric patients for the management
of complex pleural effusions.9, 13 However,
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despite a growing body of literature and gains in
clinical experience with this therapy, there are
several questions that remain unanswered to
date: timing of initiation of therapy, optimal
dosing, frequency of doses, duration of therapy,
dwell time, the need for positioning changes,
and optimal therapeutic end points. In addition,
although supported in the adult literature, the
efficacy and safety of combination therapy with
dornase alfa in pediatric patients has not yet
been established.
Researchers evaluated the timing of adminis-
tration of tPA and found that patients treated
with early intervention, defined by intervention
within 24 hours of diagnosis, experienced a
shorter duration of chest tube placement.35
Although the clinical impact of this should be
further studied, the ability to remove chest tubes
earlier may improve patient comfort and patient
mobility, and decrease analgesic dosing. Further,
cost and duration of hospital stay may be less-
ened. Strong conclusions, however, cannot yet
be made with respect to optimal timing due to
data limited to retrospective evaluations.
The optimal dosing of tPA for pleural effusion
in pediatric patients is also debatable based on
the supporting literature. Due to heterogeneity
among the studies, the optimal dose of tPA is
unknown. Although some studies used fixed
doses across age groups, others investigated a
weight-based (0.1 mg/kg) approach.9, 31–37 The
recent 2012 APSA publication suggests a fixed
dose of 4 mg based on the available prospective
data.9, 37 However, an alternative suggested
weight-based dosing algorithm for tPA, con-
structed on extrapolation of the current data, is
displayed in Figure 1. This approach has been
used anecdotally with success at our institution
but has not been validated or vigorously studied
in a controlled manner. A prospective trial evalu-
ating the safety and efficacy of this approach is
warranted. Of note, the youngest patient
reported in the literature to receive intrapleural
tPA was 3 months, and the patient with the low-
est weight reported was 5 kg. Therefore, it is
suggested that therapy be reserved for patients
older than 3 months of age and above 5 kg in
weight. The frequency of dosing, optimal dura-
tion of therapy, and dwell time are also yet unde-
termined due to variability in study design and
published reports. However, the strongest evi-
dence supports three doses given 24 hours apart,
with a dwell time of 1 hour.37 Because the intra-
pleural pharmacokinetics of tPA are unknown,
predicting the optimal parameters for therapy is
difficult, and further studies are warranted.
Furthermore, the majority of the published
data for intrapleural tPA in pediatric patients
references a dilution of 0.1 mg/ml; this dilution
is also suggested in Figure 1 and has been used
Complicated Parapneumonic
Effusion
pH <7.2
Loculations on US/CT
Aspiration of pus
Positive gram stain
>10,000 WBC/µL
Surgical vs. Fibrinolytic 
Management?
Surgical
VATS
Open thoracotomy
Fibrinolytic
tPA x 3 total doses (every 24 hours)
Dwell time: 1 hour
5-10 kg: 1 mg in 10 mL NS
10-20 kg: 2 mg in 20 mL NS
20-30 kg: 3 mg in 30 mL NS
>30 kg: 4 mg in 40 mL NS
No clinical improvement with
residual pleural effusion on US or CT
Clinical improvement with clearance 
of pleural effusion on US or CT 
Surgical Management 
(VATS or open thoracotomy)
Continue Antibiotics
Figure 1. Proposed algorithm using weight-based dosing of tissue plasminogen activator for treatment of pleural effusion in
pediatric patients. tPA = tissue plasminogen activator; US/CT = ultrasound or computed tomography; VATS = video-assisted
thoracoscopic surgery; WBC = white blood cell; NS = normal saline.
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with success at our institution. However, manu-
facturer recommendations for dilution, based on
intravenous administration, note a final concen-
tration of 1 mg/ml, which may be diluted further
immediately before administration to a concen-
tration of 0.5 mg/ml with either dextrose 5% in
water or normal saline.21 These solutions are
stable at room temperature up to 8 hours. Alter-
native dilutions of tPA have been evaluated in
vitro; however, the effects of these dilutions have
not been evaluated clinically. In vitro data indi-
cate that a tPA concentration of 0.01 mg/ml in
normal saline is stable for up to 24 hours at
room temperature.39 In that study, protein
recovery was less than 50%; but, biologic activ-
ity of the proteins recovered was preserved.
Additional personal communication with Gen-
entech (Caroline Smith, Pharm.D., Medical
Communications Department, personal commu-
nication, March 20, 2011) suggests that tPA
remains physically and chemically stable in nor-
mal saline at 0.2 mg/ml. However, diluting tPA
to concentrations less than 0.2 mg/ml in normal
saline, less than 0.5 mg/ml in dextrose 5% in
water, or diluting with other base solutions has
reportedly resulted in protein precipitation.40
Although alternative dilutions are reported in
the clinical data, most commonly 0.1 mg/ml,
further studies to confirm retained protein activ-
ity and stability at the concentration of 0.1 mg/
ml are warranted.
The optimal therapeutic end point of intraple-
ural tPA has not been elucidated, as the pub-
lished literature is variable with respect to
clinical end points. Several end points have been
evaluated including change in pleural opacity
seen on CXR, improved chest tube drainage, res-
olution of signs and symptoms, or resolution seen
on ultrasound or CT. Determination of the opti-
mal outcome should be a focus of future studies.
Furthermore, recent adult data support the
use of intrapleural combination therapy, tPA
plus dornase alfa, for initial management of
parapneumonic effusion. However, the safety
and efficacy of this approach has not been inves-
tigated in pediatric patients. Before consistently
implementing dual intrapleural therapy in chil-
dren, supporting data must become available,
providing opportunities for future research.
Conclusion
Empyema and parapneumonic effusion are sig-
nificant complications of pediatric pneumonia.
Despite the overall decline in pneumonia rates in
children, these conditions can significantly
increase morbidity and mortality. Inadequate or
delayed treatment may lead to progressive illness;
therefore, identifying the optimal treatment in
affected children is critical. Identifying patients
who will not benefit from fibrinolytic treatment
is difficult; however, surgical procedures can
likely be reserved for patients who fail fibrinoly-
sis. Although surgical treatments such as VATS
and open thoracotomy are effective, they carry
increased risk compared with chest tube drainage
with or without fibrinolysis. Fibrinolytic agents
such as tPA can help degrade loculations and dis-
solve fibrin deposits to facilitate drainage of
purulent pleural fluid. Further large, random-
ized, prospective trials should be performed in
order to answer some of the existing ongoing
questions that remain regarding tPA therapy in
pediatric patients with pleural effusion; however,
sufficient data exist that support the use of tPA
in these patients, with demonstrated efficacy and
minimal safety concerns.
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